These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7542357)
41. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133 [TBL] [Abstract][Full Text] [Related]
42. Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells. Bregni M; Lappi DA; Siena S; Formosa A; Villa S; Soria M; Bonadonna G; Gianni AM J Natl Cancer Inst; 1988 Jun; 80(7):511-7. PubMed ID: 3259267 [TBL] [Abstract][Full Text] [Related]
43. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848 [TBL] [Abstract][Full Text] [Related]
44. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881 [TBL] [Abstract][Full Text] [Related]
45. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia. Flavell DJ; Warnes S; Noss A; Flavell SU Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737 [TBL] [Abstract][Full Text] [Related]
46. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells. Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768 [TBL] [Abstract][Full Text] [Related]
47. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647 [TBL] [Abstract][Full Text] [Related]
48. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin. Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916 [TBL] [Abstract][Full Text] [Related]
49. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Davol P; Beitz JG; Mohler M; Ying W; Cook J; Lappi DA; Frackelton AR Cancer; 1995 Jul; 76(1):79-85. PubMed ID: 8630880 [TBL] [Abstract][Full Text] [Related]
50. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855 [TBL] [Abstract][Full Text] [Related]
51. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571 [TBL] [Abstract][Full Text] [Related]
52. Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain. Ghetie V; Ghetie MA; Uhr JW; Vitetta ES J Immunol Methods; 1988 Sep; 112(2):267-77. PubMed ID: 3262139 [TBL] [Abstract][Full Text] [Related]
53. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481 [TBL] [Abstract][Full Text] [Related]
54. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice. Flavell DJ; Warnes SL; Noss AL; Flavell SU Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577 [TBL] [Abstract][Full Text] [Related]
55. Recombinant immunotoxins for treating cancer. FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034 [TBL] [Abstract][Full Text] [Related]
56. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. Tutt A; Stevenson GT; Glennie MJ J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655 [TBL] [Abstract][Full Text] [Related]
57. Augmented inhibition of tumor cell proliferation in combined use of electroporation with a plant toxin, saporin. Mashiba H; Ozaki Y; Matsunaga K Ann N Y Acad Sci; 1999; 886():233-5. PubMed ID: 10667227 [No Abstract] [Full Text] [Related]
58. Delivery of ribosome-inactivating protein toxin into cancer cells with shock waves. Kodama T; Doukas AG; Hamblin MR Cancer Lett; 2003 Jan; 189(1):69-75. PubMed ID: 12445679 [TBL] [Abstract][Full Text] [Related]
59. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice. Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691 [TBL] [Abstract][Full Text] [Related]
60. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. Engel P; Wagner N; Miller AS; Tedder TF J Exp Med; 1995 Apr; 181(4):1581-6. PubMed ID: 7535343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]